VV116 is an antiviral agent and a derivative of the antiviral prodrug remdesivir .1 It inhibits viral replication of respiratory syncytial virus (RSV) in A549 cells (EC50 = 1.01 ?M). VV116 (25 mg/kg) decreases viral replication and lung viral titer counts in a mouse model of RSV infection. It also decreases alveolar inflammation in RSV-infected mice.
1.Zhang, R., Zhang, Y., Zheng, W., et al.Oral remdesivir derivative VV116 is a potent inhibitor of respiratory syncytial virus with efficacy in mouse modelSignal Transduct. Target. Ther.7(1)123(2022)